Celgene Corp. PT Raised to $177.00 at Leerink Swann (CELG)
Investment analysts at Leerink Swann lifted their target price on shares of Celgene Corp. (NASDAQ:CELG) from $165.00 to $177.00 in a note issued to investors on Wednesday, Analyst Ratings Network.com reports. The firm currently has an “outperform” rating on the stock. Leerink Swann’s target price points to a potential upside of 21.60% from the company’s current price.
A number of other analysts have also recently weighed in on CELG. Analysts at TheStreet reiterated a “buy” rating on shares of Celgene Corp. (NASDAQ:CELG) in a research note to investors on Tuesday. Separately, analysts at Goldman Sachs Group Inc. raised their price target on shares of Celgene Corp. (NASDAQ:CELG) from $113.00 to $129.00 in a research note to investors on Wednesday, September 18th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Celgene Corp. (NASDAQ:CELG) in a research note to investors on Tuesday, September 10th. They now have a $156.00 price target on the stock.
Six investment analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $142.48.
Shares of Celgene Corp. (NASDAQ:CELG) traded down 0.60% on Wednesday, hitting $145.562. 1,954,335 shares of the company’s stock traded hands. Celgene Corp. has a 52-week low of $71.23 and a 52-week high of $151.95. The stock has a 50-day moving average of $142.8 and a 200-day moving average of $128.0. The company has a market cap of $59.866 billion and a P/E ratio of 40.95.
Celgene Corp. (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 25th. The company reported $1.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.44 by $0.08. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the company posted $1.22 earnings per share. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $5.97 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.